Last reviewed · How we verify
NCT04849767: Trans&VIH
National Survey About Trajectory and Life Conditions of HIV Trans People in France
trial testing Questionnaire in HIV Seropositivity in 536 participants. Completed in 31 December 2023.
31 July 2022
Quick facts
| Lead sponsor | ANRS, Emerging Infectious Diseases |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 536 |
| Start date | 1 October 2020 |
| Primary completion | 31 July 2022 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across France |
Drugs / interventions tested
- Questionnaire
Conditions studied
- HIV Seropositivity — all drugs for HIV Seropositivity →
Sponsor
ANRS, Emerging Infectious Diseases — full company profile →
Who can join
18 and older, any sex, with HIV Seropositivity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
TRANS\&VIH is a national survey that will explore condition of vulnerability and trajectory of transgender people living with HIV. To fulfill this purpose, clinical data from medical registry and socio-behavioral information collected through questionnaire, will help to explore this questions about vulnerability and condition of transgender people living with HIV.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Living conditions, HIV and gender affirmation care pathways of transgender people living with HIV in France: a nationwide, comprehensive, cross-sectional, community-based research protocol (ANRS Trans&HIV).
Mora M, Rincon G, Bourrelly M, Maradan G, et al · · 2021 · cited 3× · PMID 34916316 · DOI 10.1136/bmjopen-2021-052691 -
Beyond the Individual: The Weight of Social and Structural Determinants of Depression Among Transgender Women Living with HIV in France (ANRS-Trans&HIV).
Van Huizen R, Annequin M, Mora M, Faye A, et al · · 2026 · PMID 42249232 · DOI 10.1007/s10461-026-05176-5 -
Socioeconomic marginalization, social exclusion, and engagement in transactional sex among transgender women living with HIV: the role of multidimensional gender affirmation.
Van Huizen R, Annequin M, Mora M, Faye A, et al · · 2025 · PMID 41024590 · DOI 10.1080/09540121.2025.2560094
Verify or expand the search:
- PubMed search for NCT04849767
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Questionnaire
Trials testing the same drug.
- NCT04466371 — Perceptions of Undergraduate Students and Teaching Staff on Online Teaching · suspended
- NCT07089953 — Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits: a Randomiz · NA · not yet recruiting
- NCT07418775 — Tumor Genomics, Individual Risk Factors, and External Drivers of Health on Health Outcomes for Patients With Meningioma · not yet recruiting
- NCT07226804 — Nanosecond Pulsed Field Ablation in the Management of Benign Thyroid Nodules · not yet recruiting
- NCT07532954 — The Impact Of A Patient Support Community On Patients With Neuroendocrine Cervical Cancer: NECC Peer Support · recruiting
Other recruiting trials for HIV Seropositivity
Currently open trials in the same condition.
- NCT06799650 — Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIV · Phase 2 · recruiting
- NCT05122026 — Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics · Phase 1, PHASE2 · active not recruiting
- NCT05118490 — Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Is · Phase 4 · active not recruiting
- NCT05723653 — Hybrid Type I Effectiveness-Implementation Trial of a Social Network Support Intervention · NA · recruiting
- NCT04832477 — Assessing the PrEP Care Cascade Among Black Men and Transwomen in the Southeastern US · NA · active not recruiting
Other ANRS, Emerging Infectious Diseases trials
Trials by the same sponsor.
- NCT07098481 — Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy · Phase 4 · not yet recruiting
- NCT06913959 — HIV-1 Non-group M in Cameroon : Study of Genotypic and Phylogenetic Diversity (OBSOCAM) · not yet recruiting
- NCT07113106 — Dose Escalation Trial of CD40.Pan.CoV Vaccine, Adjuvanted or Not, as a Booster in Adult Healthy Volunteers · Phase 1, PHASE2 · recruiting
- NCT05222945 — A Study to Determine the Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Pa · NA · not yet recruiting
- NCT06522256 — Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of H · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04849767 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ANRS, Emerging Infectious Diseases
- Last refreshed: 12 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04849767.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing